

**Basingstoke, Southampton and Winchester
District Prescribing Committee (DPC)
Recommendations of the meeting of 8 October 2013**

Supported or limited support, e.g. specialist recommendation/initiation

- **Lisdexamfetamine for the treatment of ADHD in children aged 6 and over** – supported for use locally in line with its licensed indications (when previous methylphenidate treatment is considered clinically inadequate). The shared care guidelines, including a GP summary version, are being updated to include lisdexamfetamine.
- **Azathioprine / mercaptopurine shared care guidelines**- approved and agreement that mercaptopurine should be classified as 'amber'.
- **Hydroxychloroquine shared care guidelines** – approved.
- **Sulfasalazine shared care guidelines** – approved.
- **Local shared care guidelines** are available at:
http://www.westhampshireccg.nhs.uk/documents/cat_view/84-medicines/87-shared-care-guidelines

Not Supported currently

- **Linacotide for IBS**- Not routinely supported for use locally, a possible niche role to be discussed with specialists at the December meeting.
- **Dapoxetine for the treatment of premature ejaculation** – the Committee will evaluate the evidence for this newly licensed agent at its next meeting.

Information / Reminders / Updates/ Safety Messages / NICE

- **Vitamins in Age Related Macular Degeneration, local guidance updated to reflect recent trial evidence** - Following a detailed appraisal of the evidence, it was agreed that these may be prescribed locally (although unlicensed) for a very specific group of patients in whom there is some evidence of benefit. **Specifically, patients with 'category 4' disease who have advanced disease in one eye only (advanced lesions or visual acuity <20/32).** In these patients vitamins may help prevent advanced disease and deterioration of visual acuity in the other eye. **'Viteyes 2 formula'** is the preferred product as it is least expensive and contains the correct combination of vitamins and zinc. Unlike previous AMD vitamins it can be given to previous or current smokers as it no longer contains beta-carotene. In other patient groups, (categories 1-3), there is no convincing evidence to support prescribing currently, but patients may opt to purchase these OTC. **Prescribing in 'category 4' patients normally initiated on secondary care advice. Patients should be reviewed regularly and 'treatment' discontinued if found to be of no benefit.**
- **Dapagliflozin in type 2 diabetes**- The Committee recommended that this new agent remains 'amber' (specialist recommendation only) for the time being, until further local experience is gained.
- **NICE clinical guidelines; urinary incontinence in women** – the implications for the choice of antimuscarinic agent to be discussed with local specialists.
- **The Wessex Regional Medicines Information Centre** telephone number has changed. The new number is 023 8120 6908/9. The Centre can also be contacted by email – medicinesinformation@uhs.nhs.uk